Wedbush lowered the firm’s price target on Kura Oncology (KURA) to $36 from $38 and keeps an Outperform rating on the shares after the company reported fourth quarter financials and provided corporate updates. Komzifti sales for the quarter were $2.1M following approval in early November. While the firm notes strong Revuforj sales, it remains confident in Komzifti’s profile and continues to expect a market-leading share in the r/r NPM1m space.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology reports inducement grants under Nasdaq listing rule
- Kura Oncology Earnings Call Highlights Comzifty Launch
- Early Komzifti Traction and Clinical Catalysts Underpin Buy Rating and 2028 Growth Outlook
- Kura Oncology: Early KOMZIFTI Launch Momentum, Robust AML Data, and Strong Cash Runway Underpin Buy Rating
- Kura Oncology reports Q4 EPS (92c), consensus (49c)